Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the Elderly
Open Access
- 1 March 2006
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 13 (2) , 78-83
- https://doi.org/10.1111/j.1708-8305.2006.00001.x
Abstract
Background. Protection against hepatitis A virus (HAV) in the elderly is becoming more important as more senior travelers visit areas of high HAV endemKeywords
This publication has 28 references indexed in Scilit:
- Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A VaccineClinical Infectious Diseases, 2003
- Travel Vaccines and Elderly Persons: Review of Vaccines Available in the United StatesClinical Infectious Diseases, 2001
- Hepatitis AThe Lancet, 1998
- Immunogenicity and protectivity of a new liposomal hepatitis A vaccineVaccine, 1997
- Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trialVaccine, 1996
- Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in ThaisVaccine, 1995
- Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months laterJournal of Medical Virology, 1994
- Inactivated virosome hepatitis A vaccineThe Lancet, 1994
- Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overviewJournal of Hepatology, 1993
- Simultaneous active and passive immunization against hepatitis A studied in a population of travellersVaccine, 1993